A Phase Ib Exploratory Trial of SP 333 in Patients with Ulcerative Colitis
Phase of Trial: Phase I
Latest Information Update: 25 Feb 2016
At a glance
- Drugs Dolcanatide (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept
- Sponsors Synergy Pharmaceuticals Inc
- 25 Feb 2016 Planned number of patients changed from 24 to 28, as reported by Synergy Pharmaceuticals media release.
- 11 Jan 2016 According to a Synergy Pharmaceuticals media release, the company announced positive data from this trial (n=28) for the treatment of mild-to-moderate ulcerative colitis.
- 11 May 2015 Recruitment is continuing, according to a Synergy Pharmaceuticals media release.